News

Biosensors said that Leaders is the first head-to-head randomized study between the two drug-eluting stent systems (DES) in a ‘real world, all comers’ population using clinical results as

The project, named Debio 0826, could lead to the development of potential therapeutic compounds and to the identification of new targets to fight cancer stem cells. Following the

This trial is a single arm, two-stage, open-label, Phase II study of Reolysin given intravenously with paclitaxel and carboplatin every three weeks. Patients will receive four to six

The financing will take Calabar’s product through a Phase II study with repeated dosing. The active drug, physostigmine, a cholinesterase inhibitor, targets the minor salivary glands with a

The patients will be treated with OX914 in a disease model for inflammatory airway disease. Approximately 36 patients with seasonal allergic rhinitis will be given placebo or OX914

Symbion CP Holdings (Symbion Consumer) manufactures, markets and distributes nutraceuticals and over the counter brands throughout Australia and New Zealand. It is reported that Symbion Consumer has a

Taxotere is already approved in Japan for the treatment of breast cancer, non-small cell lung, gastric, head and neck, ovarian, esophageal and endometrial cancers. This new approval is

Surface Imaging Systems (SIS) will be renamed Bruker Nano and will operate under its previous management. Frank Burgaezy, executive vice president of Bruker AXS, said: “The new Bruker

The overall results demonstrated no statistically significant differences between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) in rates of death or myocardial infarction (MI). The